Cytek Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	193.02	164.04	127.95	92.84	57.88
Revenue Growth (YoY)	17.67%	28.20%	37.82%	60.39%	-
Cost of Revenue	83.59	63.06	48.81	41.13	29.21
Gross Profit	109.43	100.97	79.14	51.71	28.67
Selling, General & Admin	93.12	67.92	45.55	24.36	16.98
Research & Development	44.15	34.86	24.44	13.69	8.93
Other Operating Expenses	0	0	0	0	20.02
Operating Expenses	137.27	102.78	69.99	38.05	45.93
Operating Income	-27.85	-1.8	9.16	13.66	-17.26
Interest Expense / Income	2.07	2.57	1.74	0.33	0
Other Expense / Income	-14.21	-5.73	1.5	-1.1	-0.96
Pretax Income	-15.71	1.35	5.91	14.43	-16.29
Income Tax	-3.56	-1.22	2.91	-4.98	0.53
Net Income	-12.15	2.58	3	19.41	-16.83
Preferred Dividends	0	0	3	16.2	0
Net Income Common	-12.15	2.58	0	3.22	-16.83
Shares Outstanding (Basic)	135	135	77	29	21
Shares Outstanding (Diluted)	135	139	82	33	21
Shares Change	-2.37%	69.93%	150.13%	55.61%	-
EPS (Basic)	-0.09	0.02	-	0.11	-0.80
EPS (Diluted)	-0.09	0.02	-	0.10	-0.80
Free Cash Flow	0.45	-22.1	0.27	13.61	-14.72
Free Cash Flow Per Share	0.00	-0.16	0.00	0.47	-0.70
Gross Margin	56.69%	61.56%	61.86%	55.70%	49.54%
Operating Margin	-14.43%	-1.10%	7.16%	14.71%	-29.81%
Profit Margin	-6.29%	1.57%	-	3.46%	-29.07%
Free Cash Flow Margin	0.24%	-13.47%	0.21%	14.66%	-25.43%
Effective Tax Rate	-	-90.53%	49.24%	-34.52%	-
EBITDA	-4.41	9.58	8.9	15.37	-15.98
EBITDA Margin	-2.28%	5.84%	6.95%	16.55%	-27.61%
Depreciation & Amortization	9.23	5.66	1.24	0.6	0.31
EBIT	-13.64	3.93	7.65	14.76	-16.29
EBIT Margin	-7.07%	2.39%	5.98%	15.90%	-28.15%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).